Sign up for updates

Your personal data will be processed according to the privacy policy

SPUTNIK LIGHT

The revolutionary one-shot vaccine.

Learn more
HUMAN ADENOVIRUSES – A WELL-TESTED TECHNOLOGY PLATFORM WITH SUBSTANTIATED, LONG-TERM SAFETY
 
Human
adenovirus
Chimpanzee
adenovirus
Messenger RNA
(mRNA)
Approved antiviral medications based on the platform
3 vaccines
to treat the Ebola virus:
more than 60,000
people vaccinated (Russia, China, African countries)
NO
NO
Approved cancer medications that use this platform
NO
NO
Years since the beginning of widescale use of drugs based on the platform
17 years
(drugs to treat
cancer)
Not used
Not used
Studies that have been completed, or in progress now, on long-term safety for the drugs (the absence of any risks of carcinogenicity or a decline in fertility)
NO
NO
Experience of commercial production of the drug
NO
NO
Number of completed Phase 3 clinical trials – verification of safety, efficacy, and therapeutic effect of the drug
0
0
Number of clinical trials involving this platform
Number of people tested in the context of completed clinical trials
Potential number of people to be tested as part of scheduled clinical trials
The number of scientific articles on each platform
353 *
134
109

Clinical trials statistics are based on clinicaltrials.gov data found as a result of search queries that contained the names of the platforms: human adenoviral vector (Ad5, Ad26, and others), chimpanzee adenoviral vector (ChAd3, ChAd63, and others), and mRNA vaccine.
Scientific articles statistics are based on pubmed.ncbi.nlm.nih.gov data found as a result of search queries that contained the names of the platforms.

* Selected examples of articles on the safety of human adenovirus vectors (77 articles)

Proven vector technology based on human adenovirus

The use of adenovirus vector technology for vector vaccines has been gaining momentum since the 1980s, and is safe and effective, which has been proven in multiple studies.

Learn more
About gamaleya national center

The Gamaleya National Center of Epidemiology and Microbiology is the world’s leading research institution founded in 1891.

The center runs one of the unique “virus libraries” in the world and has its own vaccine production facility. Gamaleya Research Center has recently received an international patent for Ebola vaccine using adenovirus vector.

Learn more
Clinical trials

The vaccine has received a registration certificate from the Russian Ministry of Health and under emergency rules adopted during the COVID-19 pandemic can be used to vaccinate the population in Russia. Sputnik V is one of the three vaccines in the world with efficacy of over 90%. Sputnik V’s efficacy was validated by internationally peer reviewed data published in The Lancet.

Learn more
Partnerships

Russia is open to international cooperation in combating the global threat of the COVID-19 pandemic and other future epidemics. We are actively cooperating with more than 14 countries producing our vaccine abroad, including India, China, Brazil, Mexico, Egypt, Iran, Italy, South Korea, Argentina, Kazakhstan, the Republic of Belarus, Serbia, Turkey, Vietnam, etc. We are looking forward to new partners willing to join this initiative and help us save lives.

Learn more
TESTIMONIALS

Message has been successfully sent!

Thank you!
You have been subscribed